MX343505B - Metodos y composiciones para inhibir la transmision del vih. - Google Patents

Metodos y composiciones para inhibir la transmision del vih.

Info

Publication number
MX343505B
MX343505B MX2012011574A MX2012011574A MX343505B MX 343505 B MX343505 B MX 343505B MX 2012011574 A MX2012011574 A MX 2012011574A MX 2012011574 A MX2012011574 A MX 2012011574A MX 343505 B MX343505 B MX 343505B
Authority
MX
Mexico
Prior art keywords
hiv
env
human
protein
fragment
Prior art date
Application number
MX2012011574A
Other languages
English (en)
Spanish (es)
Other versions
MX2012011574A (es
Inventor
Thomas Rawlin Grant
Francis John Purcell Damian
John Center Robert
Kramski Marit
Michael Robins-Browne Roy
Lichti Gottfried
Original Assignee
Immuron Ltd *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuron Ltd * filed Critical Immuron Ltd *
Publication of MX2012011574A publication Critical patent/MX2012011574A/es
Publication of MX343505B publication Critical patent/MX343505B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2012011574A 2010-04-09 2011-04-11 Metodos y composiciones para inhibir la transmision del vih. MX343505B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32239910P 2010-04-09 2010-04-09
PCT/AU2011/000407 WO2011123900A1 (en) 2010-04-09 2011-04-11 Methods and compositions for inhibiting hiv transmission

Publications (2)

Publication Number Publication Date
MX2012011574A MX2012011574A (es) 2013-03-05
MX343505B true MX343505B (es) 2016-11-04

Family

ID=44761932

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011574A MX343505B (es) 2010-04-09 2011-04-11 Metodos y composiciones para inhibir la transmision del vih.

Country Status (12)

Country Link
US (1) US20130022619A1 (enExample)
EP (1) EP2555798B1 (enExample)
JP (1) JP6026402B2 (enExample)
CN (1) CN103167881B (enExample)
AP (1) AP3469A (enExample)
AU (2) AU2011238431B2 (enExample)
BR (1) BR112012025678A2 (enExample)
CA (1) CA2795853A1 (enExample)
MX (1) MX343505B (enExample)
RU (1) RU2594249C2 (enExample)
WO (1) WO2011123900A1 (enExample)
ZA (1) ZA201207790B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2925471A1 (en) 2013-09-27 2015-04-02 Duke University Hiv-1 mother-to-child transmission correlates of protection and vaccine
CN103736100B (zh) * 2013-12-25 2017-06-09 南方医科大学 预防hiv性传播的杀微生物剂酸酐修饰抗sevi多克隆抗体
PH12018500645B1 (en) * 2015-09-24 2022-10-21 Abvitro Llc Hiv antibody compositions and methods of use
WO2017062070A1 (en) * 2015-10-07 2017-04-13 Eca Medical Instruments Gearless compact torque drive
US10973679B2 (en) * 2016-02-12 2021-04-13 Adam Arreola STD detecting condom
AU2021289612A1 (en) * 2020-06-10 2023-01-19 The University Of Melbourne HIV-1 antibodies
US20240218052A1 (en) 2021-05-12 2024-07-04 Applied Biomedical Science Institute Methods of screening and expression of disulfide-bonded binding polypeptides
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
JP7421610B1 (ja) 2022-08-18 2024-01-24 株式会社マーベラス ゲーム装置
EP4619430A1 (en) 2022-11-16 2025-09-24 Applied Biomedical Science Institute Fusion polypeptides and binding peptides and methods for producing and using same
WO2026073047A1 (en) 2024-09-27 2026-04-02 Applied Biomedical Science Institute Methods of screening and expressing cis-display libraries of disulfide-rich polypeptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039957A (en) * 1993-12-10 2000-03-21 United States Of America, As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
HK1047300A1 (zh) * 1999-06-24 2003-02-14 The Johns Hopkins University 预防经上皮传染hiv的组合物与方法
WO2002026212A2 (en) * 2000-09-28 2002-04-04 Chiron Corporation Microparticle compositions and methods for the manufacture thereof
CA2667358A1 (en) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
CA2704059A1 (en) * 2007-10-30 2009-05-07 International Aids Vaccine Initiative Antigen-antibody complexes as hiv-1 vaccines
CA2739905A1 (en) * 2008-10-30 2010-08-26 Dana-Farber Cancer Institute Mimotopes of hiv env

Also Published As

Publication number Publication date
AU2017265055A1 (en) 2019-06-06
EP2555798A4 (en) 2013-11-20
RU2594249C2 (ru) 2016-08-10
MX2012011574A (es) 2013-03-05
JP2013523783A (ja) 2013-06-17
JP6026402B2 (ja) 2016-11-16
AU2011238431B2 (en) 2016-10-06
RU2012142999A (ru) 2014-05-20
EP2555798A1 (en) 2013-02-13
US20130022619A1 (en) 2013-01-24
CA2795853A1 (en) 2011-10-13
EP2555798B1 (en) 2016-06-22
WO2011123900A1 (en) 2011-10-13
ZA201207790B (en) 2013-06-26
AU2011238431A1 (en) 2012-11-08
AP2012006519A0 (en) 2012-10-31
CN103167881A (zh) 2013-06-19
BR112012025678A2 (pt) 2017-07-18
CN103167881B (zh) 2017-06-16
AP3469A (en) 2015-11-30

Similar Documents

Publication Publication Date Title
CY1124043T1 (el) Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων
EA202190365A1 (ru) Способы изготовления пакетов-мессенджеров растений
CY1123462T1 (el) Αντισωματα που εξουδετερωνουν ισχυρα τον ιο ηπατιτιδας β και χρησεις αυτων
CY1121672T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
JP2013523783A5 (enExample)
WO2013006688A3 (en) N-terminal deleted gp120 immunogens
MX2020011717A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
CY1121323T1 (el) Αντισωματα εξουδετερωσης του ιου ανθρωπινης ανοσοανεπαρκειας (hiv)
CY1119055T1 (el) Αντισωματα που προσδενονται στην il-17a και στην il-17f
MX2021006756A (es) Anticuerpos que neutralizan el virus de la hepatitis b y usos de los mismos.
CL2014002415A1 (es) Composición inmunogénica que permite aumentar una respuesta inmunitaria a un patógeno, particularmente viral, que comprende una glicoproteína antigénica del patógeno, donde la glicoproteina está parcialmente glicosilada en al menos un sitio de glicosilación; y vacuna útil para inmunizar un mamífero (div. sol. n° 2354-11).
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP4549461A3 (en) Human immunodeficiency virus (hiv)-neutralizing antibodies
AR099855A1 (es) Anticuerpos hemaglutinina del virus antiinfluenza b y métodos de uso
MX352478B (es) Proteina vp6 de la capside de norovirus y rotavirus para el uso como vacuna combinada.
EA201892233A1 (ru) Композиции и способы, связанные с иммуногенами вич-1
EP4043031A3 (en) Zika viral antigen constructs
CL2023000539A1 (es) Moléculas de unión a antígeno multi-específicas contra el vih y métodos de uso
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
Valdez et al. Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains
EP3830108A4 (en) GENETIC ANTIBODIES AGAINST HIV-ENV
EA202090319A1 (ru) Пептидные конъюгаты, способ конъюгации и их использование
WO2016130560A3 (en) Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats
RU2012142999A (ru) Способы и композиции для предотвращения передачи вич-инфекции
PH12020500414A1 (en) Method for producing influenza ha split vaccine

Legal Events

Date Code Title Description
FG Grant or registration